SPLITOAK STRATEGIES LLC

Lobbying for BRISTOL-MYERS SQUIBB · Global biopharmaceutical company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Jan 20, 2026

Bills named in this filing 1

HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

Lobbying activity 1

Medicare/Medicaid

Value of prescription drugs and patient access Issues related to Medicaid, Medicare Parts B & D H.R. 1 U.S. Competitiveness issues

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.